PMID- 36065100
OWN - NLM
STAT- MEDLINE
DCOM- 20220908
LR  - 20221212
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 43
IP  - 5
DP  - 2022 Sep 1
TI  - Serum thymus and activation-regulated chemokine (TARC) levels correlate with 
      atopic dermatitis disease severity in patients < 6 months.
PG  - 461-467
LID - 10.2500/aap.2022.43.220034 [doi]
AB  - Background: Atopic dermatitis (AD) may develop by 6 months of age, and its 
      severity assessment is essential for appropriate treatments. Scoring Atopic 
      Dermatitis (SCORAD) is suggested to evaluate the severity of AD but is cumbersome 
      for routine clinical use. The serum thymus and activation-regulated chemokine 
      (TARC) is used as a marker of AD severity. However, the normal range of the TARC 
      levels varies by age, and its usefulness for the evaluation of AD severity has 
      not been established in patients ages < 6 months. Here, we evaluated the 
      correlation between serum TARC levels and SCORAD scores in early infancy and 
      sought the optimal cutoff level to indicate AD severity. Methods: The subjects 
      were 35 patients with AD (16 girls and 19 boys; 3-5 months of age) who visited 
      our clinic between April 2015 and March 2017. All the patients were physically 
      examined by a board-certified allergist. The AD severity was determined by using 
      the SCORAD, together with serum levels of TARC, total immunoglobulin E (IgE), 
      lactate dehydrogenase, and peripheral eosinophil counts. Receiver operating 
      characteristic curve analysis was performed to determine the cutoff levels of 
      serum TARC to indicate AD severity. Results: Significant correlations were 
      observed between SCORAD scores and the serum TARC levels, peripheral eosinophil 
      counts, and serum IgE levels (r = 0.640, r = 0.723, r = 0.533, respectively). The 
      optimal cutoff levels of serum TARC to indicate mild and severe AD were <3523 
      pg/mL (area under the curve [AUC] = 0.856) and >6192 pg/mL (AUC = 0.833), 
      respectively. Conclusion: Although this study had limitations, we suggest that 
      serum TARC is useful as a marker of AD severity in patients <6 months of age.
FAU - Koizumi, Munemitsu
AU  - Koizumi M
AD  - From the Department of Pediatrics, Ehime Prefectural Central Hospital, Matsuyama, 
      Ehime, Japan.
FAU - Kuzume, Kazuyo
AU  - Kuzume K
AD  - From the Department of Pediatrics, Ehime Prefectural Central Hospital, Matsuyama, 
      Ehime, Japan.
FAU - Ishida, Yasushi
AU  - Ishida Y
AD  - From the Department of Pediatrics, Ehime Prefectural Central Hospital, Matsuyama, 
      Ehime, Japan.
FAU - Midoro-Horiuti, Terumi
AU  - Midoro-Horiuti T
AD  - Department of Pediatrics, The University of Texas Medical Branch, Galveston, 
      Texas.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Biomarkers)
RN  - 0 (CCL17 protein, human)
RN  - 0 (Chemokine CCL17)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Biomarkers/blood/metabolism
MH  - *Chemokine CCL17/blood
MH  - *Dermatitis, Atopic/blood/diagnosis/metabolism
MH  - Female
MH  - Humans
MH  - Immunoglobulin E
MH  - Infant
MH  - Leukocyte Count
MH  - Male
MH  - Severity of Illness Index
EDAT- 2022/09/07 06:00
MHDA- 2022/09/09 06:00
CRDT- 2022/09/06 00:32
PHST- 2022/09/06 00:32 [entrez]
PHST- 2022/09/07 06:00 [pubmed]
PHST- 2022/09/09 06:00 [medline]
AID - 10.2500/aap.2022.43.220034 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2022 Sep 1;43(5):461-467. doi: 10.2500/aap.2022.43.220034.